Glucotrack, Inc. Files Q2 2024 10-Q Report

TL;DR

Glucotrack (GCTK) filed its Q2 10-Q. Check financials for performance update.

AI Summary

Glucotrack, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Integrity Applications, Inc., is based in Rutherford, NJ. The filing covers financial information for the second quarter and the first half of 2024, comparing it to the same periods in 2023. Specific financial details like revenue, net income, and cash flow are not provided in this header information.

Why It Matters

This filing provides investors with an update on Glucotrack, Inc.'s financial performance and position for the second quarter of 2024, crucial for assessing the company's health and future prospects.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information which can reveal significant performance changes, but without specific financial data in the provided text, the risk level is assessed as medium.

Key Numbers

• Q2 2024 — Reporting Period (Financial performance for the second quarter of 2024 is detailed in this filing.)
• H1 2024 — Reporting Period (Financial performance for the first half of 2024 is detailed in this filing.)
• 2023 — Comparison Period (Financials from 2023 are used for comparison in the 10-Q.)

Key Players & Entities

• Glucotrack, Inc. (company) — Filer of the 10-Q report
• Integrity Applications, Inc. (company) — Former name of Glucotrack, Inc.
• Rutherford, NJ (location) — Business and mailing address of Glucotrack, Inc.
• 20240630 (date) — End of the reporting period for the 10-Q
• 20240813 (date) — Date the 10-Q was filed

FAQ

Key Financial Figures

• $1 — 9 ) (*) Represents amount lower than $1. The accompanying notes are an integr

Filing Documents

• form10-q.htm (10-Q) — 813KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 4KB
• ex32-2.htm (EX-32.2) — 5KB
• 0001493152-24-031610.txt ( ) — 3473KB
• gctk-20240630.xsd (EX-101.SCH) — 24KB
• gctk-20240630_cal.xml (EX-101.CAL) — 32KB
• gctk-20240630_def.xml (EX-101.DEF) — 93KB
• gctk-20240630_lab.xml (EX-101.LAB) — 214KB
• gctk-20240630_pre.xml (EX-101.PRE) — 159KB
• form10-q_htm.xml (XML) — 481KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 4

Financial Statements

Item 1. Financial Statements. 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations and Comprehensive Loss 5 Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 18

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 22

Controls and Procedures

Item 4. Controls and Procedures. 23

- OTHER INFORMATION

PART II - OTHER INFORMATION 24

Legal Proceedings

Item 1. Legal Proceedings 24

Risk Factors

Item 1A. Risk Factors 24

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 25

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 25

Other Information

Item 5. Other Information 25

Exhibits

Item 6. Exhibits. 26 EXHIBIT INDEX 26

SIGNATURES

SIGNATURES 26 2 CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes forward-looking statements. These forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding our future activities, events or developments, including such things as future revenues, product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words "believe," "expect," "intend," "anticipate," "estimate," "plan," "may," "will," "could," "would," "should" and other similar words and phrases or the negative of such terms, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form 10-Q are based on certain historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary

View Full Filing

View this 10-Q filing on SEC EDGAR